Key Updates
FXI has advanced 2.32% since the last report to $39.55, marking a strong start to 2026 with YTD gains of 3.29%. The rally reflects improving fundamentals as China's manufacturing PMI expanded for the first time in nine months at 50.1 in December, while the yuan strengthened past the key 7-per-dollar threshold for its largest annual gain since 2020. Chinese equities are on track for their strongest annual performance since 2017, with the MSCI China Index rising approximately 28% in 2025. However, modest consumer subsidies of $9 billion for 2026 and accelerating industrial profit declines of 13.1% in November signal Beijing's cautious policy approach and persistent structural headwinds in the economy.
Current Trend
FXI demonstrates positive momentum across all timeframes: +3.29% (1-day), +2.59% (5-day), +0.87% (1-month), and +7.80% (6-month). The ETF has recovered strongly from the late-December correction referenced in the December 16 report, when it traded at $37.88. Current price action at $39.55 represents a 4.4% advance from that level, testing resistance near the $39-40 zone. The YTD gain of 3.29% suggests continuation of the bullish trend established in Q4 2024, though the ETF remains below previous highs near $40-41 reached in mid-December. Technical momentum indicators show strengthening as the price consolidates gains above the $39 support level.
Investment Thesis
The investment thesis centers on China's transition from stimulus-dependent growth to structural economic transformation through advanced manufacturing, technology self-sufficiency, and capital market reforms. Key pillars include: (1) Government initiatives to boost corporate payouts, with Chinese companies projected to spend approximately 3.6 trillion yuan ($509 billion) on dividends and buybacks in 2025, representing a 20% increase; (2) Strategic focus on national priority sectors including semiconductors, AI, and renewable energy, evidenced by SMIC's $5.8 billion consolidation and accelerating M&A activity totaling $385 billion in China transactions; (3) Export diversification beyond the U.S., with China achieving a historic $1.08 trillion trade surplus while reducing U.S. shipment dependence; (4) Currency strength supporting capital inflows, with the yuan posting its largest annual gain since 2020; (5) Market structure improvements driving institutional participation, with Asia-Pacific M&A reaching $1.3 trillion in 2025, up 21% year-over-year.
Thesis Status
The thesis is strengthening as multiple catalysts converge. The MSCI China Index's 28% gain in 2025 validates the structural improvement narrative, while M&A activity surging 83.56% in major asset restructurings demonstrates accelerating corporate transformation. However, execution risks persist. The modest $9 billion consumer subsidy package for 2026 represents a fraction of 2025's stimulus spending, suggesting Beijing sees limited urgency for aggressive support despite industrial profits declining 13.1% in November. The divergence between equity market performance and underlying profit growth creates vulnerability. Currency strength, while supportive of capital flows, may pressure exporters—a critical consideration given China's record trade surplus. The thesis remains intact but requires continued policy support and margin improvement from the anti-involution campaign to sustain valuation multiples.
Key Drivers
Manufacturing Recovery: China's manufacturing PMI expanded to 50.1 in December from 49.2 in November, marking the first expansion in nine months and supporting President Xi's assertion that China is on track to meet its 5% economic growth target for 2025. This recovery provides fundamental support for industrial and materials sectors within FXI's portfolio.
Currency Strength: The yuan strengthened past the key 7-per-dollar threshold, positioning for its largest annual gain since 2020. The PBOC's measured approach balances currency appreciation with export competitiveness concerns, while technical indicators show the dollar is most oversold against the yuan since 2018, suggesting potential for continued strength into 2026.
Technology Self-Sufficiency: SMIC's $5.8 billion acquisition of SMNC's remaining stake consolidates China's semiconductor manufacturing capacity, with the subsidiary generating $1.24 billion in revenue with 22% year-over-year growth. This aligns with China's strategic push for technology independence amid U.S. export restrictions.
Capital Market Reforms: M&A activity surged 83.56% in major asset restructurings to 134 cases in the first three quarters of 2025, driven by comprehensive CSRC policy support. Cross-border M&A momentum accelerated with over 100 listed companies launching overseas deals valued at more than one trillion yuan since September 2024.
Export Diversification: China achieved a historic $1.08 trillion trade surplus for the first eleven months, despite U.S. shipments declining nearly 29% year-over-year. Morgan Stanley projects China's global export market share will increase from 15% to 16.5% by 2030, driven by advanced manufacturing in EVs, robotics, and batteries.
Shareholder Returns Initiative: Chinese companies are projected to spend approximately 3.6 trillion yuan on dividends and buybacks in 2025, representing a 20% increase that significantly exceeds estimated mid-single-digit earnings growth. The government's campaign against "involution" is expected to improve profit margins and reduce wasteful capital expenditure.
Technical Analysis
FXI is trading at $39.55, up 3.29% on the day and establishing a higher low pattern above the $37.88 level reached on December 16. The ETF has reclaimed the $39 psychological support level and is testing resistance in the $39.50-40.00 zone. Short-term momentum is positive across all timeframes, with the 5-day advance of 2.59% confirming upward trajectory. The 6-month gain of 7.80% places the ETF in a consolidation phase following the sharp rally from late September through mid-December 2025. Volume patterns suggest institutional accumulation, consistent with the broader narrative of improving sentiment toward Chinese equities. Key resistance levels are $40.00 (previous December high) and $41.00 (psychological barrier), while support is established at $39.00 (current consolidation base) and $37.50 (December low). The price structure suggests a bullish continuation pattern, though overbought conditions on shorter timeframes may warrant near-term consolidation before the next leg higher.
Bull Case
- Sector Leadership in Materials and Healthcare: Materials sector gained approximately 108% driven by record commodity prices, while healthcare rebounded 50% as Chinese biotech firms captured 48% of global out-licensing deal value. This broad-based sectoral strength within FXI's holdings provides multiple growth drivers beyond cyclical recovery.
- M&A-Driven Value Realization: Asia-Pacific M&A reached $1.3 trillion in 2025, with China transactions totaling $385 billion, up 19% from 2024. Private equity activity in semiconductors, AI, and renewable energy, combined with multinational restructurings like Starbucks' $4 billion China stake sale, signals improving corporate governance and valuation discovery.
- Technology Ecosystem Consolidation: SMIC's $5.8 billion SMNC acquisition consolidates semiconductor capacity, with the subsidiary generating 22% revenue growth. Collaboration on Huawei's CloudMatrix 384 system and Alibaba's 5nm AI chip demonstrates accelerating progress toward technology self-sufficiency, reducing vulnerability to U.S. restrictions.
- Shareholder Value Framework: Chinese companies projected to spend 3.6 trillion yuan on dividends and buybacks in 2025, a 20% increase exceeding earnings growth. The anti-involution campaign is expected to improve margins by reducing wasteful capex, with fixed asset investment already declining 1.7% year-over-year in the first ten months of 2025.
- Export Market Diversification: China achieved a historic $1.08 trillion trade surplus despite U.S. shipments declining 29%, with successful market diversification across Southeast Asia, Africa, Europe, and Latin America. Morgan Stanley projects China's global export market share will increase from 15% to 16.5% by 2030, driven by advanced manufacturing capabilities.
Bear Case
- Industrial Profit Deterioration: China's industrial profits declined 13.1% year-over-year in November, a significant acceleration from October's 5.5% decrease, primarily driven by a 27.2% profit slump in the mining sector. This deterioration contradicts the equity market rally and signals persistent margin pressure across industrial sectors.
- Insufficient Stimulus Response: China's $9 billion consumer subsidy package for 2026 represents a fraction of 2025's stimulus spending, with the modest policy measures suggesting Beijing sees limited urgency for aggressive support. This cautious approach may prove inadequate to address structural consumption weakness amid the prolonged property downturn.
- Multinational Retreat from China: Western consumer brands face intensified competition from domestic rivals, with companies like Starbucks selling majority stakes and premium brands like Häagen-Dazs struggling to justify higher costs. This trend reflects structural challenges in China's consumer market and increasing price sensitivity, particularly in lower-tier cities.
- Geopolitical Restrictions Expansion: Taiwan brokers halted buy orders for shares linked to Chinese military companies on OFAC sanction lists, while ongoing U.S. export restrictions continue to constrain technology access. These geopolitical headwinds create persistent uncertainty for Chinese companies and may trigger additional capital flow restrictions.
- Valuation-Fundamentals Disconnect: MSCI China Index rose approximately 28% in 2025, yet this performance is driven primarily by multiple expansion rather than earnings growth, with corporate dividends and buybacks increasing 20% while earnings growth remains in mid-single digits. This divergence creates vulnerability to sentiment shifts if economic data continues to disappoint.